Business Wire

Alipay+ Partners With ComfortDelGro To Enable The Acceptance Of Mobile Payments From Malaysia And South Korea On Board Its Taxis

9.6.2022 02:37:00 EEST | Business Wire | Press release

Share

ComfortDelGro Taxi and Alipay+ today announced a partnership that enables mobile payments from Malaysia and South Korea, namely the Touch ‘n Go eWallet and Kakao Pay, to be accepted as cashless payment options in all its Comfort and CityCab taxis. Users of these mobile wallets can pay for the cab fare simply through the wallet apps without the need to exchange currency.

ComfortDelGro Taxi is Singapore’s largest taxi operator with a combined fleet of about 9,000 Comfort and CityCab taxis. Apart from cash payment, all ComfortDelGro Taxis currently support about 20 different cashless payment methods.

Introduced by Ant Group in 2020, Alipay+ is a suite of global cross-border digital payments and marketing solutions designed to enable businesses, especially small and medium-sized businesses, to process a wide range of mobile payment methods and reach 1 billion regional and global consumers, through one-time integration and simple technical adaption. Other leading e-wallets supported by Alipay+ include GCash (Philippines), TrueMoney (Thailand), Alipay HK (Hong Kong SAR, China) and more.

ComfortDelGro Taxi’s CEO, Mr Jackson Chia said of this partnership: “With Singapore reopening its borders, we are looking forward to having tourists come visit us. As such, our partnership with Alipay+ is a vital one as it allows cashless payment options such as Malaysia’s Touch ‘n Go eWallet and soon South Korea’s Kakao Pay available on board ComfortDelGro taxis, making it more convenient for both Malaysian and South Korean tourists to pay for taxi fares. This saves them the hassle of having to have ready cash in local currency as they are able to pay the fares upfront on their own Touch ‘n Go eWallet or Kakao Pay App.”

Speaking of the collaboration, Ms Cherry Huang, General Manager, Global Merchant Partnership, South and Southeast Asia, Ant Group said: “Transportation is an essential daily need; taxi of all modes of transportation is even more important especially to travelers. Through the support and collaboration with ComfortDelGro Taxi, we aim to deliver to all users of mobile payments supported by Alipay+ a seamless and smart digital travel experience in Singapore, where they can pay with mobile wallets they are familiar with.”

“This partnership also comes at a great time, as Singapore leads the way in opening up its borders and welcomes tourists back in the city state. We believe this is the perfect moment for tourists to reimagine travel experience post pandemic,” she added.

According to the Singapore Tourism Board, the number of visitors to Singapore in the first four months of 2022 has exceeded figures for the whole of 20211. Malaysia is ranked #3 among the top countries where the most tourists are from. South Korea is also an important traveler source market for Singapore. In pre-COVID times, South Korea was ranked 9th out of the top 15 visitor source markets in 20192.

As part of a promotional campaign to commemorate this new collaboration, Touch ‘n Go eWallet users can enjoy instant discounts of RM4 or RM6 off their total fare when they pay for their rides using their Touch ‘n Go eWallet App from today until 25 June 2022. The discounts will vary in different weeks and are limited to the first 300 transactions daily.

About Ant Group

Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.

Ant Group is the owner and operator of Alipay, the leading digital payment platform in China serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.

Ant Group has further introduced Alipay+, which provides global cross-border mobile payments and marketing solutions that connect merchant partners, especially small and medium-sized businesses, with mobile payments and other payment methods, for them to better serve their users and customers from all over the world.

About ComfortDelGro Corporation Limited

ComfortDelGro is one of the world’s largest land transport companies with a total fleet size of about 35,000 buses, taxis and rental vehicles. We also run 177km of light and heavy rail networks in Singapore and New Zealand. Our global operations span seven countries – Singapore, Australia, the United Kingdom, New Zealand, China, Ireland and Malaysia. In Singapore, the Group operates about 9,000 Comfort and CtyCab taxis. For more information, visit www.comfortdelgro.com.

1 Source: The Straits Times (https://www.straitstimes.com/singapore/jan-april-tourist-numbers-exceed-arrivals-for-whole-of-2021-with-easing-of-border-curbs)
2 Source: Singapore Tourism Board (https://www.stb.gov.sg/content/stb/en/media-centre/media-releases/Singapore-Tourism-Board-and-Studio-Dragon-Corporation-forge-a-three-year-partnership-to-jointly-promote-Singapore-through-branded-content.html)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media

Betty Bai
Ant Group
M: +65 9183 9108
E: guzhuang.bb@antgroup.com

Yvonne Tang / Jaycelyn Choo
Group Corporate Communications
ComfortDelGro Corporation Limited
M: +65 9754 7670 / +65 9127 0468
E: groupcorpcomms@comfortdelgro.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye